Posted by Michael Wonder on 21 May 2020
Proposal to award sole supply of infliximab in DHB hospitals
21 May 2020 - PHARMAC is proposing to award sole supply of infliximab, a biologic medicine used to treat a range of inflammatory and autoimmune conditions, from 1 September 2020.
If the proposal is approved, this would mean the Remicade brand of infliximab 100 mg injection, supplied by Janssen-Cilag (Janssen), would have Hospital Supply Status from 1 September 2020 until 30 June 2024.
